Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Orrell, Richard W ^a   Lane, R J M ^b   Ross, M ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

Amyotrophic lateral sclerosis *drug therapy; mortality ; Antioxidants *therapeutic use ; Humans; Randomized controlled trials as topic

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ALSAMIN; ALSEMET; ASCORBIC ACID; BETA CAROTENE; FREE RADICAL; METHIONINE; NIMODIPINE; PLACEBO; RILUZOLE; SELEGILINE; SELENIUM; UBIQUINONE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; COCHRANE LIBRARY; DATA EXTRACTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MONEY; MOTOR NEURON DISEASE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 37849009887     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002829.pub4     Document Type: Review

References (42)

1. Apostolski 1998 {published data only} *Apolstolski S, Markinkovic Z, Nocolic A, Blagojevic D, Spasic MB, Michelson AM. Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. Journal of Environmental Pathology, Toxicology and Oncology 1998;17(3-4):325-9.
2. Desnuelle 2001 {published and unpublished data} Desnuelle C, Dib M, Garrel C, Favier A. ALS riluzole-tocopherol study group. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & other motor neuron disorders 2001;2(1):9-18.
3. Ellis 1997 {published data only} Ellis T, Cudkowicz ME, McKenna-Yasek D, Eggelston PM, Brown RH, Cros D. Combination antioxidant therapy in amyotrophic lateral sclerosis. Neurology 1997;48:A127.
4. Graf 2005 {published data only} Graf M, Ecker D, Horowski R, Riederer P, Gerlach M, Hager C, Ludolph AC, on behalf of the German vitamin E / ALS StudyGroup. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. Journal of Neurotransmission 2005;112(5):649-60.
5. Jossan 1994 {published data only} Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE, Aquilonius SM. Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. Journal of Neural Transmission 1994;41(Supplementum):237-41.
6. Lange 1998 {published data only} Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al.Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Archives of Neurology 1998;55(1): 93-6.
7. Louwerse 1995 {published data only} Louwerse ES, Weverling GJ, Bosuyt PM, Meyjes FE, De Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Archives of Neurology 1995;52(6):559-64.
8. Mitchell 1995 {published data only} Mitchell JD, Gatt JA, Phillips TM, Houghtohn E, Rostron G, Wignall C. Cu/Zn superoxide dismutase free radicals, and motoneuron disease [Letter]. Lancet 1993;342(8878): 1051-2.
9. *Mitchell JD, Houghton E, Rostron G, Wignall C, Gatt JA, Phillips TM, et al.Serial studies of free radical and antioxidant activity in motor neurone disease and the effect of selegiline [letter]. Neurodegeneration 1995;4(2):233-5.
10. Mitchell JD, Houghton E, Rostron G, Wignall C, Phillips TM, Kilshaw J. Indices of free radical and antioxidant activity in amyotrophic lateral sclerosis. In: Clifford RoseF editor(s). ALS - from Charcot to the present and into the future. London: Smith-Gordon and Company Ltd, 1994:297-307.
11. Stevic 2001 {published data only} *Stevic Z, Nicolic A, Blagjevic D, Saicia ZS, Kocev N, Apostolski S, et al.A controlled trial of combination of methionine and antioxidants in ALS patients. Jugoslavenska Medicinska Biokemija 2001;20:223-8.
12. Stevic Z, Nicolic A, Blagojevic D, Saicic ZS, Apolstolski S, Spasic M. A controlled trial of combination of methionine and antioxidants in amyotrophic lateral sclerosis. Proceedings ALS/MND International Alliance Meeting, Munich, Germany. 1998.
13. Ascherio 2005 Ascherio A, Weisskopf MG, O'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE, et al.Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals of Neurology 2005;57(1):104-10.
14. Chio 1998 *Chio A, Cucatto A, Terreni AA, Schiffer D. Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Italian Journal of Neurological Science 1998;19(6):363-6.
15. Dorman 1969 *Dorman JD, Engel WK, Fried DM. Therapeutic trial in amyotrophic lateral sclerosis. JAMA 1969;209(2):257-8.
16. Engel WK, Hogenhuis LAH, Collis WJ, Schalch DS, Barlow MH, Gold GN, et al.Metabolic studies and therapeutic trials in amyotrophic lateral sclerosis. In: NorrisFH, KurlandLT editor(s). Motor neuron diseases. New York: Grune and Stratton, 1969:199-208.
17. Janik 1996 *Janik P, Kwiecinski H, Jamrozik Z, Czyzewski K, Opuchlik A. A randomised trial of antioxidative therapy in amyotrophic lateral sclerosis. Journal of Neurology 1996;243(Suppl):25.
18. Kwiecinski H, Janik P, Jamrozik Z, Opuchlik A. The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trial [Polish]. Neurologia i Neurochirurgia Polska 2001; Supplement 1:101-6.
19. Mazzini 1994 Mazzini L, Testa D, Balzarini C, Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. Journal of Neurology 1994;241(4):223-7.
20. Norris 1987 *Norris FH, Denys EH. Nutritional supplements in amyotrophic lateral sclerosis. Advances in Experimental Medicine and Biology 1987;209:183-9.
21. Quick 1969 *Quick. Pancreatic dysfunction in amyotrophic lateral sclerosis. In: NorrisFH, KurlandLT editor(s). Motor neuron diseases. New York: Grune and Stratton, 1969:189-98.
22. Szczudlik 1998 *Szczudilk A, Tomi B, Slowik A, Kasprzyk K. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 1998;T32(XLVIII):821-9.
23. Vyth 1996 *Vyth A, Timmer JG, Bossuyt PMM, Louwerse ES, de Jong JM. Survival in patients with amyotrophic lateral sclerosis treated with an array of antioxidants. Journal of the Neurological Sciences 1996;39 Suppl:99-103.
24. Wechsler 1940 *Wechsler IS. The treatment of amyotrophic lateral sclerosis with vitamin E (tocopherols). American Journal of Medical Science 1940;200:765-78.
25. Beckman 1993 Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364(6438):584.
26. Bergeron 1996 Bergeron C, Petrunka C, Weyer L. Oxidative stress plays a role in the pathogenesis of familial and sporadic amyotrophic lateral sclerosis. In: FiskumG editor(s). Neurodegenerative Diseases. NewYork: Plenum Press, 1996:275-80.
27. Brooks 1994 Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. Journal of the Neurological Sciences 1994;124 Suppl:96-107.
28. Eisen 1998 Eisen A, Krieger C. In: EisenA, KriegerC editor(s). Amyotrophic lateral sclerosis: a synthesis of research and clinical practice. Cambridge: Cambridge University Press, 1998.
29. Greenberg 2005 Greenberg ER. Vitamin E supplements: good in theory, but is the theory good?. Annals of Internal Medicine 2004;142(1):75-6.
30. Gurney 1996 Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology 1996;39(2):147-57.
31. Halliwell 2001 Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs and Aging 2001;18(6):685-716.
32. Ince 1994 Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD, Markesbery WR. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neuroscience Letters 1994;182(1):87-90.
33. Knoll 1989 Knoll J. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurologica Scandinavica. Supplementum 1989;126:83-91.
34. Lacomblez 1996 Lacomblez L, Bensimon G, Leigh PN, Guillet P, Menninger V, The ALS/Riluzole Study Group II. A dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347(9013):1425-31.
35. Logroscino 2005 Logroscino G, Beghi E, Zoccolella S, Palagano R, Fraddosio A, Simone IL, et al.the SLAP registry. Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. Journal of Neurology Neurosurgery and Psychiatry 2005;76(8):1094-8.
36. Miller 2004 Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane review). Cochrane Database of Systematic Reviews 2004, Issue 3.
37. Miller 2005 Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2004;142:37-46.
38. Mitchell 1987 Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurology Clinics 1987;5(1):43-60.
39. Pioro 2000 Pioro EP. Antioxidant therapy in ALS. ALS and other motor neuron disorders 2000;1 Suppl 4:5-12.
40. Rosen 1993 Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al.Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362(6415) :59-62.
41. Sardesi 1995 Sardesai VM. Role of antioxidants in health maintenance. Nutrition in Clinical Practice 1995;10(1):19-25.
42. Sejvar 2005 Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB. Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 2005;25(3):144-52.